PMID- 35035511
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - Yijin-Tang Attenuates Cigarette Smoke and Lipopolysaccharide-Induced Chronic 
      Obstructive Pulmonary Disease in Mice.
PG  - 7902920
LID - 10.1155/2022/7902920 [doi]
LID - 7902920
AB  - BACKGROUND: Chronic obstructive pulmonary disease (COPD) refers to a lung 
      disorder associated with symptoms of dyspnea, cough, and sputum production. 
      Traditionally, Yijin-tang (YJT), a mixture of Pinellia ternate, Poria cocos, 
      ginger, Chinese liquorice, and tangerine peel, has been prescribed for the 
      treatment of respiratory system diseases caused by dampness phlegm. This 
      experiment investigated the therapeutic effect of YJT in a mouse model of 
      cigarette smoke (CS)- and lipopolysaccharide (LPS)-induced COPD. METHODS: COPD 
      was induced by exposing mice to CS for 1 hour per day for 8 weeks, with 
      intranasal delivery of LPS on weeks 1, 3, 5, and 7. YJT was administered at doses 
      of 100 and 200 mg/kg 1 hour before CS exposure for the last 4 weeks. RESULTS: YJT 
      significantly suppressed CS- and LPS-induced increases in inflammatory cell 
      counts and reduced interleukin-1 beta (IL-1beta), IL-6, tumor necrosis factor-alpha 
      (TNF-alpha), and monocyte chemoattractant protein-1 (MCP-1) levels in bronchoalveolar 
      lavage fluid (BALF) and lung tissue. In addition, YJT not only decreased airway 
      wall thickness, average alveolar intercept, and lung fibrosis, but it also 
      suppressed the expression of matrix metallopeptidase (MMP)-7, MMP-9, and 
      transforming growth factor-B (TGF-beta) and collagen deposition. Moreover, YJT 
      suppressed phosphorylation of nuclear factor-kappa B (NF-kappaB) as well as 
      expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase 
      (iNOS). CONCLUSION: Collectively, our findings show that YJT attenuates 
      respiratory inflammation and airway remodeling caused by CS and LPS exposure; 
      therefore, therapeutic applications in COPD can be considered.
CI  - Copyright (c) 2022 Jinhyung Rho et al.
FAU - Rho, Jinhyung
AU  - Rho J
AD  - Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam 
      National University, Daejeon, Republic of Korea.
FAU - Seo, Chang-Seob
AU  - Seo CS
AD  - KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, 
      Republic of Korea.
FAU - Hong, Eun-Ju
AU  - Hong EJ
AD  - Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam 
      National University, Daejeon, Republic of Korea.
FAU - Baek, Eun Bok
AU  - Baek EB
AD  - Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam 
      National University, Daejeon, Republic of Korea.
FAU - Jung, Eunhye
AU  - Jung E
AD  - Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam 
      National University, Daejeon, Republic of Korea.
FAU - Park, Suyoung
AU  - Park S
AD  - Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam 
      National University, Daejeon, Republic of Korea.
FAU - Lee, Mee-Young
AU  - Lee MY
AD  - KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, 
      Republic of Korea.
FAU - Kwun, Hyo-Jung
AU  - Kwun HJ
AUID- ORCID: 0000-0001-5927-1970
AD  - Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam 
      National University, Daejeon, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20220105
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8754600
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/01/18 06:00
MHDA- 2022/01/18 06:01
PMCR- 2022/01/05
CRDT- 2022/01/17 05:55
PHST- 2021/09/13 00:00 [received]
PHST- 2021/11/17 00:00 [revised]
PHST- 2021/12/09 00:00 [accepted]
PHST- 2022/01/17 05:55 [entrez]
PHST- 2022/01/18 06:00 [pubmed]
PHST- 2022/01/18 06:01 [medline]
PHST- 2022/01/05 00:00 [pmc-release]
AID - 10.1155/2022/7902920 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Jan 5;2022:7902920. doi: 
      10.1155/2022/7902920. eCollection 2022.